Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 38-42

  Roh, Yoon Seok ^a   Seki, Ekihiro ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Intestinal microflora; Liver fibrosis; LPS; MyD88; TLR4

Indexed keywords

BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; FATTY ACID; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALCOHOL LIVER DISEASE; APOPTOSIS; BACTERIAL TRANSLOCATION; CARCINOGENESIS; CHRONIC LIVER DISEASE; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; KUPFFER CELL; LIPID DIET; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84880425458     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12019     Document Type: Review

References (59)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
2. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract. 2010; 2010: 240365.
3. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007; 13: 851-856.
4. Zhang Q, Raoof M, Chen Y etal. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-107.
5. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335.
6. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 2005; 79: 7269-7272.
7. Seki E, Tsutsui H, Nakano H etal. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J. Immunol. 2001; 166: 2651-2657.
8. Wu J, Meng Z, Jiang M etal. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010; 129: 363-374.
9. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-1055.
10. Watanabe A, Hashmi A, Gomes DA etal. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-1518.
11. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-1332.
12. Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol. Res. Pract. 2010; 2010: 710381.
13. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J. Gastroenterol. 2010; 16: 1321-1329.
14. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644.
15. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J. Hepatol. 1991; 12: 162-169.
16. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34: 101-108.
17. Yan AW, Fouts DE, Brandl J etal. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105.
18. Uesugi T, Froh M, Arteel GE etal. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J. Immunol. 2002; 168: 2963-2969.
19. Yin M, Bradford BU, Wheeler MD etal. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 2001; 166: 4737-4742.
20. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-224.
21. Pennington HL, Hall PM, Wilce PA, Worrall S. Ethanol feeding enhances inflammatory cytokine expression in lipopolysaccharide-induced hepatitis. J. Gastroenterol. Hepatol. 1997; 12: 305-313.
22. von Montfort C, Beier JI, Guo L, Kaiser JP, Arteel GE. Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G1227-1234.
23. Inokuchi S, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol. Clin. Exp. Res. 2011; 35: 1509-1518.
24. Hritz I, Mandrekar P, Velayudham A etal. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008; 48: 1224-1231.
25. Frances R, Benlloch S, Zapater P etal. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484-491.
26. Frances R, Munoz C, Zapater P etal. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860-864.
27. Romics L Jr, Dolganiuc A, Kodys K etal. Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in mice. Hepatology 2004; 40: 555-564.
28. Gustot T, Lemmers A, Moreno C etal. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43: 989-1000.
29. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
30. Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol. Res. Pract. 2010; 2010: 362847.
31. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
32. Brun P, Castagliuolo I, Di Leo V etal. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292: G518-525.
33. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol. 2008; 14: 313-317.
34. Farhadi A, Gundlapalli S, Shaikh M etal. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008; 28: 1026-1033.
35. Csak T, Velayudham A, Hritz I etal. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 300: G433-441.
36. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.
37. Ye D, Li FY, Lam KS etal. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058-1067.
38. Miura K, Kodama Y, Inokuchi S etal. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-34 e7.
39. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. TLR2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation. Hepatology 2013; 57: 577-589.
40. Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 2006; 281: 26865-26875.
41. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006; 116: 3015-3025.
42. Zu L, He J, Jiang H, Xu C, Pu S, Xu G. Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. J. Biol. Chem. 2009; 284: 5915-5926.
43. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr. 2002; 21: 219-223.
44. Lee JY, Ye J, Gao Z etal. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 2003; 278: 37041-37051.
45. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001; 276: 16683-16689.
46. Schaeffler A, Gross P, Buettner R etal. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009; 126: 233-245.
47. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 1944-1949.
48. Stacey KJ, Young GR, Clark F etal. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 2003; 170: 3614-3620.
49. Alderton GK. Inflammation: the gut takes a toll on liver cancer. Nat. Rev. Cancer 2012; 12: 379.
50. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
51. Lee JS, Chu IS, Mikaelyan A etal. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 2004; 36: 1306-1311.
52. Naugler WE, Sakurai T, Kim S etal. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
53. Dapito DH, Mencin A, Gwak GY etal. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
54. Yu LX, Yan HX, Liu Q etal. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010; 52: 1322-1333.
55. Machida K, Tsukamoto H, Mkrtchyan H etal. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 1548-1553.
56. Inokuchi S, Aoyama T, Miura K etal. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 844-849.
57. Liu S, Gallo DJ, Green AM etal. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect. Immun. 2002; 70: 3433-3442.
58. Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J. Interferon Cytokine Res. 2000; 20: 915-921.
59. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008; 99: 836-842.